Summary of the Rights Issue

• The net proceeds from the Rights Issue will be used for business development and marketing, personnel and operations, R&D and product development, regulatory and clinical investments, operational efficiency and supply chain flexibility, and to ensure financial stability.
• The Rights Issue comprises up to 5,333,582 shares of series B with a subscription price of SEK 8.0 per share. If the Rights Issue is fully subscribed, the Company will receive approximately SEK 42.6 million before deduction of costs related to the Rights Issue.
• Each share, regardless of series, in the Company held on the record date November 13, 2025 entitles the holder to one (1) subscription right. Four (4) subscription rights entitle the holder to subscribe for one (1) new share of series B.
• The last day of trading in the Company's shares including the right to participate in the Rights Issue is November 11, 2025.
• The subscription period will run from and including November 17, 2025, to and including December 1, 2025.
• Trading in subscription rights will take place on Nasdaq First North Growth Market during the period from and including November 17, 2025, to and including November 26, 2025, and trading in paid subscribed shares (BTA) will occur during the period from and including November 17, 2025, to and including December 10, 2025.
• The Rights Issue is covered by subscription commitments and guarantee commitments corresponding to 100 percent of the issue amount. However, the subscription commitments and the guarantee commitments are not secured by bank guarantees, escrow accounts, pledges or similar arrangements.
• The Board of Directors' resolution on the Rights Issue is subject to approval by an extraordinary general meeting to be held on November 10, 2025. A separate press release with the notice to the extraordinary general meeting will be published through a separate press release.
• No prospectus will be prepared in connection with the Rights Issue. The Company will prepare and publish an information document (the "Information Document") in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (the "Prospectus Regulation").

Integrum CEO Martin Hillsten comments: "The capital raising will secure the implementation of our new business strategy. We are pleased that proposed board members see the potential of Integrum and have chosen to invest by, among other things, taking over subscription rights. We look forward to delivering on the strategy with a clear commercial focus and for more and more patients to experience the benefits of Integrum's fantastic products."

Reasons for the Rights Issue and use of proceeds

Integrum is currently executing a transformative journey, moving from a development-driven company toward an effective, commercially focused organization. The new strategic direction, launched in February 2025, aims to accelerating commercialization through a focused go-to-market model built around Centers of Excellence. By focusing on selected Centers of Excellence with high-volume potential, Integrum can lay the foundation for a more profitable business. While continuing to streamline execution, improve operational efficiency and apply disciplined capital allocation. The Company builds on its strong clinical and regulatory foundation while resetting its cost structure and commercial operations to enable sustainable growth.

Since the launch of the strategy shift, Integrum has taken important steps to streamline operations, sharpen commercial focus and strengthen financial governance. The progression of the strategy shift and the implementation of cost savings are continuing according to plan and the Company has made progress, but the transformation is not yet complete. To support this transformation, Integrum is executing the Rights Issue of approximately SEK 42.6 million. The proceeds are intended to provide the financial sustainability needed to execute ongoing cost-saving initiatives, strengthen commercialization efforts and maintain focus on key markets and Centers of Excellence. The Company's aim is to achieve an efficient and financially self-sustaining organization as the ongoing transformation takes effect.

The proceeds from the Rights Issue, after deduction of costs, are intended to support the Company's transformation during at least the coming twelve months and will be allocated across the following strategic areas:

• Business Development and Marketing, approximately 20 percent,
  To drive momentum in prioritized markets, leverage Centers of Excellence and intensify commercial outreach around already initiated activities.
• Personnel and Operations, approximately 25 percent,
  To retain core competencies within an efficient structure, ensuring operational continuity and scalability as the organization transforms.
• R&D and Product Development (critical projects), approximately 15 percent,
  Focused investment only in essential development projects that directly support the existing product platform and future competitiveness.
• Regulatory and Clinical Investments, approximately 15 percent,
  To maintain Integrum's high quality standards, secure necessary product approvals and generate clinical evidence that supports reimbursement and adoption.
• Operational Efficiency and Supply Chain Flexibility, approximately 10 percent,
  To drive efficiency improvements, strengthen supply chain resilience through dual sourcing and optimize cost of goods while supporting long-term scalability.
• Working Capital, approximately 15 percent,
  To ensure financial stability during the transformation period, supporting continued execution of the Company's strategic initiatives.

Terms for the Rights Issue

The right to subscribe for shares of series B shall be granted with preferential rights to the Company's shareholders as of the record date. Each existing share, regardless of series, held in the Company on the record date of November 13, 2025, entitles the holder to one (1) subscription right. Four (4) subscription rights entitle the holder to subscribe for one (1) new share of series B at a subscription price of SEK 8.0 per share. A maximum of 5,333,582 new shares of series B will be issued in total. To the extent that new shares are not subscribed for with preferential rights, they shall be offered to shareholders and other investors who have expressed an interest in subscribing for shares in the Rights Issue. Upon full subscription, the Rights Issue will provide the Company with approximately SEK 42.6 million before deduction of transaction costs.

The subscription period will run from November 17, 2025, through December 1, 2025. Subscription rights that are not exercised during the subscription period will thereafter become void and lose their value. Trading in subscription rights will take place on Nasdaq First North Growth Market from November 17, 2025, through November 26, 2025, and trading in BTA (paid subscribed shares) will occur from November 17, 2025, through December 10, 2025.

Allotment Principles

If not all shares are subscribed for by exercise of subscription rights, allotment of the remaining shares shall be made within the highest amount of the Rights Issue:

• firstly, to those who have subscribed for shares by exercise of subscription rights (regardless of whether they were shareholders on the record date or not) and who have applied for subscription of shares without exercise of subscription rights and if allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of subscription rights that each and every one of those, who have applied for subscription of shares without exercise of subscription rights, have exercised for subscription of shares;
• secondly, to those who have applied for subscription of shares without exercise of subscription rights, and if allocation to these cannot be made in full, allocation shall be made pro rata in relation to the total number of shares for which each subscriber has applied; and
• thirdly, any remaining shares, up to the amount covered by subscription commitments and guarantee commitments, shall be allotted to those who have entered into guarantee commitments, pro rata in relation to such commitments.

To the extent that allotment in any section above cannot be done pro rata, allotment shall be determined by drawing of lots.

Subscription commitments and guarantee commitments

The Rights Issue is covered by subscription commitments, and guarantee commitments corresponding to 100 percent of the total issue amount. Certain existing shareholders, including Rickard Brånemark, Molcap Invest AB and Gerhard Dal, have undertaken to subscribe for shares in the Rights Issue. Certain existing and proposed members of the board have entered into subscription commitments through agreements of taking over subscription rights, enabled by the principal shareholder's transfer of subscription rights. In total, the subscription commitments represent approximately 31 percent of the Rights Issue, corresponding to approximately SEK 13 million.

In addition to the aforementioned subscription commitments, certain existing shareholders, including Gerhard Dal, Molcap Invest AB and Nowo Fund Management AB, and several external parties have provided guarantee commitments amounting to approximately SEK 30 million, corresponding to approximately 69 percent of the Rights Issue. A cash guarantee fee of seven (7.0) percent of the guaranteed amount will be paid for the guarantee commitments. No compensation will be paid for the subscription commitments. However, the entered subscription commitments and guarantee commitments are not secured by bank guarantees, escrow funds, pledges, or any similar arrangements.

Additional information regarding the parties that have entered into subscription commitments and guarantee commitments will be disclosed in the Information Document. 

Change in share capital and number of shares and dilution

In the event that the Rights Issue is fully subscribed, the Company's share capital will increase by SEK 373,350.74, from SEK 1,493,402.96 to SEK 1,866,753.70, through the issuance of 5,333,582 shares of series B. As a result, the number of shares will increase from 21,334,328 shares to 26,667,910 shares, whereof 640,000 shares of series A and 26,027,910 shares of series B. The number of votes in the Company increases from 27,094,328 with 5,333,582 to a total of 32,427,910 votes. For existing shareholders who do not participate in the Rights Issue, this corresponds to a dilution effect of approximately 20.0 percent of the capital and 16.4 percent of the voting rights in the Company upon full subscription. 

Information Document

No prospectus will be prepared in connection with the Rights Issue. The Company will prepare and publish the Information Document in the form provided for in Annex IX of the Prospectus Regulation. The Information Document will be made available on the Company's website before the subscription period in the Rights Issue begins.

Extraordinary general meeting

The Board of Directors' resolution regarding the Rights Issue is subject to approval by an extraordinary general meeting, which is expected to be held on November 10, 2025. Shareholders representing approximately 28.2 percent of the shares and approximately 43.5 percent of the votes in the Company have undertaken or expressed intention to vote in favor of the Rights Issue. Notice of the extraordinary general meeting will be published through a separate press release.

Preliminary time table for the Rights Issue

Earlier publication of quarterly report

To enable participation in the Rights Issue by board members, the Company's board of directors has resolved to publish the Company's Q2 report on November 21, 2025.

Advisors

Integrum has engaged DNB Carnegie Investment Bank AB (publ), and Setterwalls Advokatbyrå AB as financial and legal advisors in connection with the Rights Issue.